For instance, hypoglycemia is a common side effect of sulfonylureas, but is rare with GLP-1 agonists and DPP-4 inhibitors, which might mediate the relative risk difference when compared to sulfonylureas.30 This evidence concerns the gene GLP1R and Hypoglycemia.